Financial PerformanceNatera delivered very strong metrics across the board, reaffirming its position as a top pick with a Buy rating and an increased price target.
Guidance And Growth PotentialThe company provided 2024 revenue guidance that was meaningfully ahead of our estimate and consensus, indicating potential for revenue and gross margin outperformance.
Product And Market ExpansionNatera received Medicare coverage for Signatera in two new indications, potentially expanding its market.